Gene Therapy Pros and Cons – Biolyse

Over the years genetic disorders and gene-related illness have been responsible for high mortality rates and reduced quality of life. Some of the congenital abnormalities manifest quite early, and there are minimal hopes for survival in these children, this causes much pain to their families because management option is limited and there is very little at their disposal to modify such conditions. Scientists are developing a relatively new technique that will give hope to the hopeless and make life better. Genetic disorders can be due to misalignment, missing genes or excess of a gene. Genetic therapy works at the elementary level of heredity to replace the defective genes with new ones.

Gene therapy is the insertion of new functional genes into an individuals cell or tissue to replace the defective one and modify a hereditary disease. This is a new research area, and much research projects are still in the infancy or trial stages; however, expectations are high, and we would potentially do away with genetic diseases soon enough. Developed in 1972, gene therapy can be of two type; somatic gene therapy and germline gene therapy. It is especially promising in treating genetic disorders such as muscular dystrophy and cystic fibrosis. Critics have their say and look at the two sides of the story will lead us to weigh risk: benefit ration. Gene therapy pros and cons can be quite decisive on whether or not we should embrace gene therapy.

Research into gene therapy has been ongoing for decades now, and there is light at the end of the tunnel as gene therapy is associated with the following advantages;

Genetic defect occur even after thorough screening and many people have their lives compromised or limited by such disorders. In the United States alone as at 2009, 3% congenital disabilities were recorded in all births, the joy of having a child is suddenly lost and replaced with the agony and struggle of maintaining such demanding life. Individual patient and family are pessimistic as efforts to change the condition by traversing through different levels of healthcare are always thwarted since no cure exists for such situations. Gene therapy intent to correct such birth defects responsible for more than half of infant mortality is laudable. We can be confident that all the unborn babies will be delivered safely and grow to their prime. Besides, gene therapy promises a cure for the chronic illnesses that are currently incurable for example cancer that causes agonizing pain in many.

By replacing a defective gene with a functional gene in a disease like cystic fibrosis, there are limited chances of remission, and this is usually a one-off treatment that will see you symptom-free for life. Furthermore, gene therapy is not just a remedy to the individual suffering from a given condition, but it covers the entire generation. When you remove a gene predisposing one to breast cancer they wont transfer the defective genes to their offspring but the new functional gene.

Some of the initially incurable diseases can be managed and possibly eliminated when we involve gene therapy. Alterations to gene especially the reproductive genes using the germline method can help in avoiding transmission of defective genes and thus no further incidences of disease. Parkinsons disease, Huntingtons disease, and Alzheimers disease are but a few conditions that are likely to be eliminated by gene therapy.

Not only does gene therapy focus on diseases. Conditions that may make life unlimited such as infertility are also accounted for, and it is projected that soon enough gene therapy should activate reproductive genes and allow you to have children.

Gene therapy promises much potential in the medical field ranging from relieving the pill burden to modifying phenotypes in cosmetology.

Although gene therapy has a potential for treating several ailments and improving life, this is a relatively new technique and involve several safety concerns thus it should be carefully embraced. Some of the notable disadvantages of gene therapy include;

As at now, gene therapy is at the developmental stages, and most experiments are done on the animals with the hope that success will be reflected in humans. However, anything can happen, and gene therapy can fail to work thus limit your capabilities or even worsen the condition. Incompatibility issues and immune response can also lead to failure of the procedure. The massive ongoing research will leverage the concerns and provide a technological-based method with a high certainty of results.

The cost of performing gene therapy is likely to be high because it involves sophisticated equipment and high-level expertise. Such a fee may not be affordable to many, and this will create socioeconomic segregation as the rich will be disease-free while the poor remain to bear the burden of such illness. A solution to this would possibly be extensively integrating technology in the process since technologically based therapy may prove more cost-effective even when compared to the other therapeutic options.

Superb as it may look, gene therapy may be short-lived. Nature is unpredictable, and sometimes it may take its course for the worse. Just like the antibiotics were novel at the time of invention, it is possible that the use of gene therapy may gain resistance as well. There is no guarantee that gene therapy will fulfill its expectations to treat explicit disorders, performing gene adjustments could create new defects for future generations without realizing it; thus it can be a double-edged sword.

One of the greatest hindrance to the advancement of gene therapy is the opposition on the basis that it can open room for unethical science which may be demeaning to the human race. The thoughts that gene therapy creates a perfected human has been very controversial.

Read the rest here:

Gene Therapy Pros and Cons - Biolyse

Syrian refugee is thriving five years after last-gasp gene therapy – STAT – STAT

In the summer of 2015, a 7-year-old named Hassan was admitted to the burn unit of the Ruhr University Childrens Hospital in Bochum, Germany, with red, oozing wounds from head to toe.

It wasnt a fire that took his skin. It was a bacterial infection, resulting from an incurable genetic disorder. Called junctional epidermolysis bullosa, the condition deprives the skin of a protein needed to hold its layers together and leads to large, painful lesions. For kids, its often fatal. And indeed, Hassans doctors told his parents, Syrian refugees who had fled to Germany, the young boy was dying.

The doctors tried one last thing to save him. They cut out a tiny, unblistered patch of skin from the childs groin and sent it to the laboratory of Michele de Luca, an Italian stem cell expert who heads the Center for Regenerative Medicine at the University of Modena and Reggio Emilia. De Lucas team used a viral vector to ferry into Hassans skin cells a functional version of the gene LAMB3, which codes for laminin, the protein that anchors the surface of the skin to the layers below.

advertisement

Then the scientists grew the modified cells into sheets big enough for Ruhr University plastic surgeons Tobias Hirsch and Maximilian Kueckelhaus to graft onto Hassans raw, bedridden body, which they did over the course of that October, November, and the following January.

It worked better than the boys doctors could have imagined. In 2017, de Luca, Hirsch, Kueckelhaus, and their colleagues reported that Hassan was doing well, living like a normal boy in his lab-grown skin. At the time though, there was still a big question on all their minds: How long would it last? Would the transgenic stem cells keep replenishing the skin or would they sputter out? Or worse could they trigger a cascade of cancer-causing reactions?

advertisement

Today, the same team is out with an update. Five years and five months after the initial intervention, Hassan is still, for the most part, thriving in fully functional skin that has grown with the now-teenager. He is attending school, and playing sports with his friends and siblings, though he avoids swimming due to blistering in the areas that werent replaced by the lab-grown skin. One of his favorite activities is a pedal-powered go kart. There are no signs his modified stem cells have lost their steam, and no traces of tumors to be found.

The encouraging follow-up data has been instrumental in moving forward a larger clinical trial of the approach, offering hope to the 500,000 epidermolysis bullosa patients worldwide currently living without treatment options.

We were astonished by the speedy recovery, Kueckelhaus, now at University Hospital Muenster, told STAT via email. But experience from skin transplantation in other settings made him and his colleagues wary of the grafts failing as the months and years wore on. Thankfully, wrote Kueckelhaus, those fears never materialized. We are very happy to be able to prove that none of these complications appeared and the genetically modified skin remains 100% stable. The chances are good that he will be able to live a relatively normal life.

Over the last five years, Hassans team of doctors and researchers has put his new skin through a battery of tests checking it for sensitivity to hot and cold, water retention, pigmentation and hemoglobin levels, and if it had developed all the structures youd expect healthy skin to have, including sweat glands and hair follicles. Across the board, the engineered skin appeared normal, without the need for moisturizers or medical ointments. The only flaw they found was that Hassans skin wasnt as sensitive to fine touch, especially in his lower right leg. This mild neuropathy they attributed not to the graft itself, but to how that limb was prepared doctors used a more aggressive technique that might have damaged the nerves there.

The team also used molecular techniques to trace the cells theyd grown in the lab as they divided and expanded over Hassans body. They found that all the different kinds of cells composing the boys new skin were being generated by a small pool of self-renewing stem cells called holoclone-forming cells, carrying the Italian teams genetic correction.

This was quite an insight into the biology of the epidermis, said de Luca. Its an insight he expects will have huge consequences for any efforts to advance similar gene therapies for treating other diseases affecting the skin. You have to have the holoclone-forming cells in your culture if you want to have long-lasting epidermis, he said.

The approach pioneered by de Lucas team will soon be headed for its biggest clinical test yet, after nearly a decade of fits and starts. They expect to begin recruiting for a multi-center Phase 2/3 trial sometime next year.

De Luca first successfully treated a junctional EB patient in 2005. But then a change to European Union laws governing cell and gene therapies forced his team to stop work while they found ways to comply with the new rules. It took years of paperwork, building a manufacturing facility, and spinning out a small biotech company called Holostem to be ready to begin clinical research again. Hassan came along right as they were gearing up for a Phase 1 trial, but data from the boys case, which was granted approval under a compassionate use provision, convinced regulators that the cell grafts could move to larger, more pivotal trials, according to de Luca.

We didnt cure the disease, he told STAT. But the skin has been restored, basically permanently. We did not observe a single blister in five years. The wound healing is normal, the skin is robust. From this point of view, the quality of life is not even comparable to what it was before.

Read this article:

Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT

New Technology is One Step Closer to Targeted Gene Therapy – Caltech

Gene therapy is a powerful developing technology that has the potential to address myriad diseases. For example, Huntington's disease, a neurodegenerative disorder, is caused by a mutation in a single gene, and if researchers could go into specific cells and correct that defect, theoretically those cells could regain normal function.

A major challenge, however, has been creating the right "delivery vehicles" that can carry genes and molecules into the cells that need treatment, while avoiding the cells that do not.

Now, a team led by Caltech researchers has developed a gene-delivery system that can specifically target brain cells while avoiding the liver. This is important because a gene therapy intended to treat a disorder in the brain, for example, could also have the side effect of creating a toxic immune response in the liver, hence the desire to find delivery vehicles that only go to their intended target. The findings were shown in both mouse and marmoset models, an important step towards translating the technology into humans.

A paper describing the new findings appears in the journal Nature Neuroscience on December 9. The research was led by Viviana Gradinaru (BS '05), professor of neuroscience and biological engineering, and director of the Center for Molecular and Cellular Neuroscience.

The key to this technology is the use of adeno-associated viruses, or AAVs, which have long been considered promising candidates for use as delivery vehicles. Over millions of years of evolution, viruses have evolved efficient ways to gain access into human cells, and for decades researchers have been developing methods to harness viruses' Trojan-Horse-like abilities for human benefit.

AAVs are made up of two major components: an outer shell, called a capsid, that is built from proteins; and the genetic material encased inside the capsid. To use recombinant AAVs for gene therapy, researchers remove the virus's genetic material from the capsid and replace it with the desired cargo, such as a particular gene or coding information for small therapeutic molecules.

"Recombinant AAVs are stripped of the ability to replicate, which leaves a powerful tool that is biologically designed to gain entrance into cells," says graduate student David Goertsen, a co-first author on the paper. "We can harness that natural biology to derive specialized tools for neuroscience research and gene therapy."

The shape and composition of the capsid is a critical part of how the AAV enters into a cell. Researchers in the Gradinaru lab have been working for almost a decade on engineering AAV capsids that cross the blood-brain barrier (BBB) and to develop methods to select for and against certain traits, resulting in viral vectors more specific to certain cell types within the brain.

In the new study, the team developed BBB-crossing capsids, with one in particular AAV.CAP-B10that is efficient at getting into brain cells, specifically neurons, while avoiding many systemic targets, including liver cells. Importantly, both neuronal specificity and decreased liver targeting was shown to occur not just in mice, a common research animal, but also in laboratory marmosets.

"With these new capsids, the research community can now test multiple gene therapy strategies in rodents and marmosets and build up evidence necessary to take such strategies to the clinic," says Gradinaru. "The neuronal tropism and decreased liver targeting we were able to engineer AAV capsids for are important features that could lead to safer and more effective treatment options for brain disorders."

The development of an AAV capsid variant that works well in non-human primates is a major step towards the translation of the technology for use in humans, as previous variants of AAV capsids have been unsuccessful in non-human primates. The Gradinaru lab's systematic in vivo approach, which uses a process called directed evolution to modify AAV capsids at multiple sites has been successful in producing variants that can cross the BBBs of different strains of mice and, as shown in this study, in marmosets.

"Results from this research show that introducing diversity at multiple locations on the AAV capsid surface can increase transgene expression efficiency and neuronal specificity," says Gradinaru. "The power of AAV engineering to confer novel tropisms and tissue specificity, as we show for the brain versus the liver, has broadened potential research and pre-clinical applications that could enable new therapeutic approaches for diseases of the brain."

The paper is titled "AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset." Goertsen; Nicholas Flytzanis (PhD '18), the former scientific director of the CLARITY, Optogenetics and Vector Engineering Research(CLOVER)Center of Caltech's Beckman Institute; and former Caltech postdoctoral scholar Nick Goeden are co-first authors. Additional coauthors are graduate student Miguel Chuapoco, and collaborators Alexander Cummins, Yijing Chen, Yingying Fan, Qiangge Zhang, Jitendra Sharma, Yangyang Duan, Liping Wang, Guoping Feng, Yu Chen, Nancy Ip, and James Pickel.

Funding was provided by the Defense Advanced Research Projects Agency, the National Institutes of Health, and the National Sciences and Engineering Research Council of Canada.

Flytzanis, Goeden, and Gradinaru are co-founders of Capsida Biotherapeutics, a Caltech-led startup company formed to develop AAV research into therapeutics.

Read the rest here:

New Technology is One Step Closer to Targeted Gene Therapy - Caltech

BMS and Kite Unveil CAR-T Successes in Lymphoma – BioSpace

Jeremy Moeller/Getty Images

Significant advancements in the treatment of relapsed or refractory large B-cell lymphoma are on the horizon. At the American Society of Hematology meeting, this weekend, both Bristol Myers Squibband Kite Pharma presented promising data from CAR-T programs aimed at this disease.

At ASH, BMS unveiled data that showedBreyanzi(liso-cel), a CD19-directed CAR-T cell therapy, as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma,outperformed the current standard of carefor patients in second-line relapsed or refractory LBCL, significantly improving event-free survival (EFS). BMS said that only a small portion of patients who have relapsed or refractory large B-cell lymphoma (LBCL) experience long-term benefits with high-dose chemotherapy and stem cell transplant. Data from the pivotal Phase III TRANSFORM study showed that Breyanzi significantly improved median event-free survival with a median of 10.1 months. Standard of care treatment only offered an improvement of 2.3 months with a 65% improvement.

Data showed that 86% of Breyanzi patients achieved a complete or partial response, with 66% of patients achieving a complete response. In comparison, only 48% of standard of care patients achieved the same response, with only 39% of those reaching a complete response.

Median progression-free survival was significantly longer withBreyanzicompared to standard of care, 14.8 months vs. 5.7 months.

Additionally, results from an analysis of patient reported outcomes from the TRANSFORM study showed favorable improvement in most patient reported outcomes. That includes an improved or maintained health-related quality of life for patients who were treated with Breyanzicompared to those treated with the standard of care treatment.

Kite Pharma, a subsidiary of Gilead Sciences, showcased its own data in second-line relapsed/refractory large B-cell lymphoma (LBCL), the same indication as BMS Breyanzi. Data from the landmark Phase III ZUMA-7 study of Yescarta (axicabtagene ciloleucel) showed a 2.5 fold increase in patients who were alive at two years and had not required the need for additional cancer treatment or experienced cancer progression. Also, the data showed a four-fold greater median event-free survival for Yescarta compared to standard of care.

Kite said that improvements in EFS with Yescarta were consistent across patient subgroups, including the elderly, those with primary refractory disease, high-grade B-cell lymphoma including double-hit and triple-hit lymphoma and double expressor lymphoma.

Yescarta was the first CAR T-cell therapy to be approved by the U.S. Food and Drug Administrationfor the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Additionally, Kite announced significant long-term data showcasing the CAR-T therapys ability to provide meaningful improvements in quality of life compared with standard of care. Also at ASH, Kite unveiled data that showed Yescarta provided a five-year overall survival rate of 42%. Among those patients who saw a complete response to the CAR-T treatment, the five-year overall survival rate was 64.4%.

Perhaps most significantly, Kite said that among Yescarta patients who were still alive after five years, 92% needed no additional treatment since that first infusion of the CAR-T therapy. This suggests a potential cure for some of the patients, Kite said, in its announcement.

Other cell therapy data presented at ASH include:

bluebird Gene Therapy Improves Lives of Sickle Cell Patients

bluebird bio'slovo-celis showing promisein a Phase I/II study in sickle cell. Data from two cohorts of the largest sickle cell gene therapy program to date is showing patients treated with lovo-cel are seeing a continued complete resolution of severe vaso-occlusive events (VOE) after six years.

The VOEs are defined as episodes of acute pain with no medically determined cause other than vaso-occlusion. That means that lovo-cel, a lentiviral gene therapy, has the potential to improve day-to-day life in sickle cell patients by eliminating the painful issues associated with the disease that can occur several times per month.

Additionally, the patients have achieved near normal levels of key hemolysis markers and experienced sustained improvements in patient-reported quality of life following treatment.

The bluebird gene therapy is designed to add functional copies of a modified form of the -globin gene (A-T87Q-globin gene) into a patients blood stem cells. Once the gene is added, their red blood cells are able to produce anti-sickling hemoglobin (HbAT87Q), which reduces the sickled blood cells that cause the disease.

Janssens CAR-T Hammers Multiple Myeloma

At ASH, Janssenannounced data from a Phase Ib/II study that showed CAR-T therapy cilta-cel (ciltacabtagene autoleucel) provided anoverall response rate of 98%in patients with relapsed and/or refractory multiple myeloma.

The company said that cilta-cel, an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, showed that patients who received an infusion continued to demonstrate deep and durable responses. Data showed that 83% of patients in the study achieved a stringent complete response (sCR) at 22 months. That is an 80% increase from the 18-month median follow-up presented earlier this year at the American Society of Clinical Oncology meeting.

Also, two-year progression free survival and overall survival rates were 61% and 74%, respectively.

Poseida Sees Promise in CAR-T as it Winds Down Autologous Program

Interim results from Poseida'sPhase I/II PRIME study of P-BCMA-101for the treatment of relapsed/refractory multiple myeloma show strong anti-tumor activity in patients with advanced forms of the disease. P-BCMA-101 in combination with rituximab achieved an improved overall response rate of 78% and 100% overall survival.

P-BCMA-101 is a non-viral transposon-based autologous CAR-T. The data from the PRIME study have been used to inform the companys development of its first allogeneic program, P-BCMA-ALLO1, also being developed in the same indication. In November, Poseida announced that it iswinding down the P-BCMA-101 autologous programin favor of the allogeneic program, P-BCMA-ALLO1.

Read more here:

BMS and Kite Unveil CAR-T Successes in Lymphoma - BioSpace

CF Foundation Funding Bolsters Gene Therapy Research – Cystic Fibrosis News Today

The Cystic Fibrosis Foundationis funding three new early-stage research awards worth more than $1.8 million to bolster the development of potential gene therapies for cystic fibrosis (CF).

This funding will support critical early steps necessary for the development of genetic therapies for cystic fibrosis, William Skach, MD, executive vice-president and chief scientific officer of the CF Foundation, said in a press release. These promising programs are tackling difficult challenges such as efficient therapeutic delivery of diverse genetic cargos and evasion or modulation of the immune systems response to gene delivery vehicles.

Gene therapy works by adding a new gene or replacing or repairing a mutated gene inside cells in the body. To get gene therapy into the cells, it first must be packed into a carrier, usually a harmless virus. However, other carriers exist that may deliver gene therapy.

Carmine Therapeutics was awarded more than $766,000 to test one such alternative type of carrier. The company plans to use tiny particles, called vesicles, that naturally bud off from red blood cells to deliver a healthy copy of cystic fibrosis transmembrane conductance regulator (CFTR) the gene mutated in people with CF into lung cells. Unlike other carriers, which sometimes trigger an immune response, the vesicles are expected to be well-tolerated by the immune system, even upon repeat administration.

If a viral carrier must be used, the bodys immune response should be blocked to allow repeat administration. GenexGen was awarded close to $595,000 to develop a way to lessen the immune response to a viral carrier. The company is testing an approach that uses CRISPR a kind of molecular scissors that can cut pieces of DNA to target a certain gene that plays a key role in the immune system. The goal is to turn off that gene temporarily, thus allowing gene therapy to be delivered by a virus.

Finally, Specific Biologics was awarded more than $527,000 to test a CRISPR-based approach to make precise changes in DNA and thereby correct (edit) three common CFTR mutations in CF: G542X, R553X, and W1282X. Each of these mutations results in a stop codon in the middle of the gene and a shorter protein that ends up getting degraded by the cells. If successful, the approach is expected to work for any mutation.

The award will support preclinical testing of an inhaled medicine that uses tiny fat particles to help the gene-editing molecules enter the cells more easily.

The awards are part of the foundations Path to a Cure, an initiative whose goal is to accelerate the development of therapeutic strategies that address the root cause of CF.

See the original post here:

CF Foundation Funding Bolsters Gene Therapy Research - Cystic Fibrosis News Today

N4 Pharma to Focus Resources on Advancing Gene Therapy Work – MarketWatch

By Anthony O. Goriainoff

N4 Pharma PLC said Monday that it will focus its resources on advancing its work on gene therapy, and that it will continue its vaccine-delivery efforts in conjunction with partners and working on specific proprietary products.

The AIM-listed pharmaceutical company said the preliminary results from mouse immunogenicity studies carried out by Evotec SE using Covid-19 didn't show meaningful immunological response, and that this brought into question the whole study. The company said it will concentrate future vaccine work through its material transfer agreements [MTA] and that it was in advanced discussions with another company focusing on mRNA delivery with a view to scoping the work to be undertaken under a new MTA.

The company said that although the results on the vaccine work from Evotec were unexpected, the proof-of-concept data collated to date has been sufficient to allow it to sign MTAs with potential vaccine collaborators.

"We expect other collaborations will follow, so it makes sense to continue the vaccine platform optimization with collaborators who own their own DNA plasmids and mRNA compounds. This will allow us to focus internal efforts on developing commercial products in the gene therapy space," Chief Executive Nigel Theobald said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

See the article here:

N4 Pharma to Focus Resources on Advancing Gene Therapy Work - MarketWatch

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO – PRNewswire

Gene therapy is still in its infancy and has yet to achieve its full potential. First-generation gene therapies have been challenged by safety issues due to their inability to target cells and organs without also penetrating non-targeted cells and organs, especially the liver. Capsida's proprietary, targeted, non-invasive gene therapy technology allows more selective targeting of specific tissues and cells, overcoming many of the problems associated with first-generation gene therapies, specifically off-target cell and organ activity. In addition, it allows the gene therapy to be delivered non-invasively through intravenous (IV) administration. The company's already strong leadership team is poised to actualize the promise of gene therapy with the addition of Mr. Anastasiou and the promotions of Drs. Flytzanis and Goeden.

"I can't imagine a more exciting time to join this organization," said Mr. Anastasiou. "Capsida is enabling gene therapy to become what the industry, physicians, and patients have been dreaming it will be. Our patent-protected technology allows the targeting of cells and organs while limiting the negative impact on non-targeted areas, and can be applied across multiple therapeutic areas. Another important benefit of our technology is that we are able to deliver the gene therapy non-invasively through IV administration. I'm honored to lead this talented team to achieve Capsida's potential and to improve and even save patients' lives."

Mr. Anastasiou joins Capsida from Lundbeck, where he was an executive vice president and a member of the executive committee, reporting to the CEO. As the president of Lundbeck's U.S. and Canadian business operations, Mr. Anastasiou has built organizations from the ground up. He brings significant leadership experience managing diverse organizations and bringing them together to achieve common goals. He led as many as 1,200 employees and achieved net revenues of $1.5 billion. During his 12-year tenure at Lundbeck, Mr. Anastasiou held several progressive leadership positions, playing a pivotal role in developing and launching multiple products and building the company's cross-functional capabilities. Mr. Anastasiou serves on the Board of PhRMA and the global advisory board for the Healthcare Businesswomen's Association. Mr. Anastasiou begins his new role with Capsida on January 3, 2022.

"We're thrilled to welcome Peter as Capsida's new CEO," said Beth Seidenberg, M.D., founding managing director at Westlake Village BioPartners, one of the company's lead investors, and Capsida board member. "Peter has deep industry expertise, a broad network, and significant public company experience, which will be valuable as Capsida grows. In addition, his strong track record of success demonstrates he is a visionary leader who will be able to deliver on the promise of targeted non-invasive gene therapy to help underserved patients and achieve business success."

"During his tenure at Lundbeck, Peter has created significant shareholder value, creating and leading organizations and successful blockbuster product launches," said Clare Ozawa, Ph.D., managing director at Versant Ventures, one of Capsida's lead investors, and Capsida board member."Under Peter's leadership, we will continue to build Capsida as the industry's leading targeted, non-invasive gene therapy company with the ability to transform the lives of patients with life-threatening genetic disorders."

Prior to Lundbeck, Mr. Anastasiou held management roles at Neuronetics, Inc., Bristol-Meyers Squibb Company, and Eli Lilly and Company. He holds an MBA from the Kelley School of Business at Indiana University, and a B.A. in economics and management from Albion College.

Capsida co-founders Nicholas Flytzanis, Ph.D., promoted to CSO and Nick Goeden, Ph.D., promoted to CTO

In addition to Mr. Anastasiou's appointment, Capsida announced that Dr. Flytzanis has been promoted toCSO and Dr. Goeden has been promoted to CTO.

"The promotions of Drs. Flytzanis and Goeden are in recognition of the significant contributions they have made since co-foundingCapsida in 2019," said Mr. Anastasiou. "Their steadfast commitment to delivering on the promise of Capsida's differentiated, non-invasive gene therapy platform has been a key driver behind many of the company's early achievements."

"Drs. Flytzanis' and Goeden's strong scientific and technical expertise and know-how have already delivered results in the startup of Capsida based on Caltech'sbasic research on targeted non-invasive gene delivery to the brain," said Capsida co-founder Viviana Gradinaru, Ph.D. "Their promotions are timely as Capsida enters the phase of delivering from the lab and for the patients."

Prior to co-founding Capsida, Dr. Flytzanis served as scientific director of the CLOVER research center at the California Institute of Technology (Caltech), leading an interdisciplinary team to develop and disseminate emerging technologies focused on the cross-section of neurological research and gene therapy. His research spans the fields of tissue clearing and imaging, optogenetics and rodent behavior, and adeno-associated virus (AAV) engineering and gene therapy, with collaborations across multiple institutions. During his Ph.D., Dr. Flytzanis applied protein engineering and directed evolution across biological modalities, with a focus on developing AAVs as therapeutic tools for neurological disease.

Dr. Flytzanis holds a Ph.D. in biology from Caltech and a B.S. in biology from the Massachusetts Institute of Technology.

Prior to co-founding Capsida, Dr. Goeden led a team developing the novel adeno-associated virus (AAV) engineering technology underlying Capsida's biologically driven gene therapy platform. During his tenure as a postdoctoral fellow in Dr. Gradinaru's lab at Caltech, he developed high-throughput methods for screening combinatorial libraries to explore the AAV fitness landscape and engineered novel AAVs with high efficiency and specificity for the rodent and primate brain. During his Ph.D., Dr. Goeden developed a novel organ bioreactor to study real-time metabolomics in diseased states, exploring the relationship between gene expression and the pathophysiology of neurodevelopmental disorders.

Dr. Goeden holds a Ph.D. in neuroscience from The University of Southern California and a B.S. in biology from Caltech.

About Capsida Biotherapeutics

Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology. Visit us at http://www.capsida.com to learn more.

SOURCE Capsida Biotherapeutics

More:

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO - PRNewswire

URMC & RIT faculty awarded patent for gene transfer technology that could transform cancer therapies – URMC

The carbon nanotube device could streamline some cancer therapies like CAR T-cell therapy.

Researchers at the University of Rochester Del Monte Institute for Neuroscience and Rochester Institute of Technology have received a U.S. patent for technology designed to accelerate development of cell therapies for cancer and other bio-therapies. The technique provides a less toxic alternative to standard gene transfer techniques by using an array of carbon nanotubes to deliver DNA into primary neurons, immune cells, and stem cells.

Our goal is to provide a technology that can lower the cost and increase speed and the range of cell types that can be adapted for therapeutic use, said Ian Dickerson, Ph.D., associate professor of Neuroscience. Many new cell-based therapies depend on changing the gene expression of primary cells. These approaches range from stem cells for production of patient-specific repair tissues, to CAR T-cells used for focused cancer therapy.

Dickerson and Michael Schrlau, Ph.D., associate professor of mechanical engineering in RITs Kate Gleason College of Engineering, were recently awarded a patent for this technology. It delivers biomolecules into cells through carbon nanotube arrays. Their honeycomb of nanotubes device was first described in a 2016 study published in the journal Small.

A scanning electron micrograph (SEM) of a macrophage cell sitting on top of the bed of carbon nanotubes.

The carbon nanotubes aim to be an alternative to conventional gene transfer methods that have a number of limitations including expensive equipment, low efficiency, and results in high toxicity that damages the cells. These methods limit the types of experiments that can be done and many cells like stem cells, primary cells, and immune T-cells. With Dickersons and Schrlaus device cells are able to grow on the carbon nanotube, genes are then transferred through the tubes and taken up by the cells through endocytosis. It has been successful at culturing a number of cell types, including immune cells, stem cells, and neurons, all are typically difficult to grow and keep alive.

The initial research that lead to this device was supported in part by a $50-thousand SchmittProgram in Integrative Neuroscience pilot award from the Del Monte Institute for Neuroscience. It funded Dickersons project entitled High Efficiency Injection of Biomolecules into Uticle Cells by Carbon Nanotube Arrays. This funding enabled us to begin manufacturing these carbon nanotube devices, and test the function on cell lines, which provided preliminary data that proved the concept of carbon nanotube-mediated gene transfer would work, said Dickerson.

The researchers are now collaborating with investigators at Wilmot Cancer Institute to further explore using this device for cancer therapies like CAR T-cells. "Currently CART-cells are manufactured using a viral vector to accomplish gene transfer, said Patrick Reagan, M.D., assistant professor of Medicine at the Wilmot Cancer Institute.Gene transfer via carbon nanotubules represents a novel method of gene transfer that could make the manufacturingprocess more efficient. This is important given that many of the patients treated with CAR T-cell therapy for lymphoma and leukemia have aggressive disease and the time delays associated with CAR T-cell manufacturing can lead to adverse outcomes."

See the original post:

URMC & RIT faculty awarded patent for gene transfer technology that could transform cancer therapies - URMC

Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England…

DUBLIN--(BUSINESS WIRE)--The "Gene Editing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global gene editing market is expected to grow from $4.25 billion in 2020 to $4.53 billion in 2021 at a compound annual growth rate (CAGR) of 6.6%. The market is expected to reach $7.27 billion in 2025 at a CAGR of 12.6%.

Major players in the gene editing market are CRISPR, GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies and New England Biolabs.

The gene editing market consists of sales of gene editing technology such as CRISPR/CAS9, zinc finger nucleus, and talens and related services. Gene editing technology allows genetic material to change genetic code at particular location in a genome. It involves cell line engineering, animal genetic engineering and plant genetic engineering.

The gene editing market covered in this report is segmented by technology into CRISPR, TALEN, ZFN. It is also segmented by end users into biotechnology, pharmaceutical, contract research organization and by application into animal genetic engineering, plant genetic engineering, cell line engineering.

Infectious diseases are constantly on the rise. For instance, according to the World Health Organization (WHO), infectious diseases kill more than 17 million people per year. In addition to that, according to the AP-NORC (a research initiative by the Associated Press and the University of Chicago) survey, out of 1,067 adults in the US surveyed, 71% are in favor of gene editing for the treatment of incurable, hereditary diseases such as Huntington's disease and 67% of Americans support the use of gene editing to prevent diseases such as cancer.

Ethical issues in general public with respect to gene editing is one of the major restraining factors for the market. Many researchers and ethicist have argued against gene editing due to different reasons such as off-target effect (edits in the wrong place), mosaicism (when only some of the cells carry the edits) and safety concerns. Some even argued that gene editing will lead to the creation of classes of individuals who will be genetically modified to be able to do things that a normal human being is not supposed to do according to the laws of nature. Due to these reasons, gene editing is still not considered to be safe and effective by many nations and international organizations.

Gene editing (also called genome editing) is a group of technologies that allow the researchers to change an organism's DNA by adding, removing or altering genetic material at particular locations in the genome. The emergence of advanced genome editing techniques is one of the major trend in the gene editing market.

The new techniques in genome editing are relatively inexpensive and can be used in a variety of application areas such as improving the food supply in agriculture, rectifying specific genetic mutations in the human genome and preventing the spread of diseases. For instance, CRISPR-Cas9 is a gene editing technique and stands for Clustered Regularly Interspace Short Palindromic Repeats.

The technique uses a strand of DNA as molecular scissors used to make cuts in DNA at specific points to make space to add new genomes. This technique is faster, cheaper, more accurate and efficient than other existing genome editing methods. Companies investing in CRISPR technology are Crispr therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas medicine.

The rising infectious diseases acts as one of the major drivers of the gene editing market. Gene editing techniques are used for detection of infectious diseases such as HIV. Infectious diseases are caused by microorganisms like bacteria, viruses, fungi, and parasites. Gene therapy treats the infectious diseases by blocking the replication of the infectious agent that causes the disease at the extracellular level. Gene editing introduces new genetic material into the cells of living organisms with the intention of treating the diseases.

European regulatory framework divided gene therapy into two categories, germline gene therapy, and somatic gene therapy. In germ line gene therapy, modified genes will be passed on to next generations whereas its not the same case with somatic gene therapy. Current regulation by the EU has only allowed somatic gene therapy, therefore, germline gene therapy is banned.

The European Medical Association provides guidelines on gene therapy for preparing market authorization application to obtain approval from the authority to carry on research and development activities in gene therapy. For instance, the EU provides guidance note on gene therapy medicinal product which is intended for use in humans, defines scientific principles and provide guidance for development and evaluation of gene therapy products.

Key Topics Covered:

1. Executive Summary

2. Gene Editing Market Characteristics

3. Gene Editing Market Trends and Strategies

4. Impact Of COVID-19 On Gene Editing

5. Gene Editing Market Size and Growth

5.1. Global Gene Editing Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Gene Editing Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Gene Editing Market Segmentation

6.1. Global Gene Editing Market, Segmentation by Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.2. Global Gene Editing Market, Segmentation by End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.3. Global Gene Editing Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Gene Editing Market Regional and Country Analysis

7.1. Global Gene Editing Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Gene Editing Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ns9rjy

with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

More here:

Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England...

Bridging the cell and gene therapy gap – The Scotsman

The CGT Catapult was established to advance the growth of cell and gene therapies in the UK by bridging the gap between scientific research and full-scale commercialisation. As it prepares to open a new facility in the Edinburgh BioQuarter next summer, we put questions to its chief clinical officer Dr Jacqueline Barry.

How effective a bridge between academia and industry has CGT Catapult been?

When we were set up in 2012, there wasnt really a strong cell and gene therapy (CGT) industry. The UK is now the largest cluster for cell and gene therapies outside the United States. About 30 per cent of all CGT companies in Europe are in the UK, and the UK has representation in 12 per cent of global clinical trials. So were now becoming quite a mature industry, and the UK is known and respected globally for advanced therapies.

Our role is to create powerful collaborations which overcome challenges to the advancement of the sector. Id say weve done pretty well in bridging the gap between industry and academia, including creating new collaborations, supporting the creation of spin-out from universities and facilitating progress of companies towards commercialisation.

We continue to focus on this as a core activity for Cell and Gene Therapy Catapult.

What areas of academic need was CGT Catapult able to address?

It depends who the academics are. Some have already spun-out successful companies like Autolus Therapeutics, which announced a $250 million investment by Blackstone this month.

Another is Resolution Therapeutics, founded from a collaboration between Edinburghs Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management.

The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary campus. A further example would be Purespring Therapeutics, a spin-out from the University of Bristol, which secured one of the largest single investments to date for a new UK university biotech company.

While others are still relatively early in their product development path, we can use our facilities and expertise to accelerate them through the translation pathway.

We provide support through collaborative grants, for example, support of the design of a non-clinical testing programme, and provide commercialisation of research support for really promising technology or therapies to help them secure investment for their research.

How was CGT Catapult able to help industry to bring therapies closer to the market?

We try to anticipate barriers and then act to break them down. For example, a number of years ago we identified there wasnt enough cleanroom manufacturing space for late-stage clinical trials and early market release. In response to this barrier, we established our Manufacturing Innovation Centre in Stevenage, 30 miles north of London. This is a unique collaborative model, where we provide the support in the form of facility licensure, quality and warehouse management systems, environmental monitoring etc, while our collaborators can develop their processes and expertise within their own manufacturing module using their staff and processes.

Our collaborators having such space to build expertise and in-house knowledge is really valuable for them, and it cements their ability to manufacture and supply here in the UK.

In addition, we help with projects 100+ a year of different sizes and complexity, providing technology and process innovation solutions, or helping groups navigate the regulatory and reimbursement challenges and barriers.

How has CGT Catapult helped to foster a culture of innovation?

Innovation can mean so many different things. Technology and process innovation is important, and we help groups with process and analytical solutions. For example, weve taken processes with say 1,000 manual steps and automated the manufacture, increasing the security of the product.

Another could be in the clinical space. The Industrial Strategy Challenge Fund made funds available for the Advanced Therapy Treatment Centre network. This is truly innovative. Were working with 65 industry partners alongside the NHS to come up with solutions for these innovative but disruptive products for patients. Working hand-in-hand with industry and the NHS, we are innovating together, producing practical solutions for both parties.

What are the challenges for the NHS with these kinds of products?

These are living therapies, its disruptive and difficult to deliver these products. In addition, there is an avalanche of products coming with different product types for different indications and different patient groups.

Specialists might not be familiar with these new products. There are often complex referral pathways, so theyre only delivered from particular hospitals. There are specific regulatory and reimbursement conditions placed on the manufacturers. All these things together add complexity and require innovative solutions to not increase the burden for the NHS.

The CGT Catapult aims to help cell and gene therapies to be safer, more effective, scalable and affordable. How do you maintain research integrity and best practice in the face of that constant demand to do things better, faster, cheaper?

Were all scientists and we know this is a young field which has great promise. I think its just in everybodys DNA to ensure that your data integrity is as solid as it possibly can be.

These are quite unusual products which are designed to treat patients who are either at the end of their treatment regimen for example, treatment of a blood cancer or for the treatment of rare genetic disorders, and you want to catch their symptoms before they start impacting on their day-to-day life. So you have to act quickly, but be really confident that your data supports the use of these products.

Why is CGT Catapult coming to Edinburgh [in summer 2022]? Whats it adding?

A lot of cell and gene therapy work is currently focused in southern England, where we have also seen the third-largest cell and gene therapy cluster developing around Stevenage. There are, however, opportunities for growth and further cluster development across the UK, creating jobs and offering equity of access for patients through the UK.

The CGT Catapult will have offices and labs based in the Institute for Regeneration and Repair in the Bioquarter, Edinburgh. The University of Edinburgh and Scottish Blood Transfusion Service have considerable expertise in the development of cell and gene therapy products. Between the Scottish Centre for Regenerative Medicine and the Institute for Regeneration and Repair [currently under construction in the BioQuarter], the University of Edinburgh will have 500 stem cell scientists. Thats the biggest accumulation of stem cell scientists in Europe, and possibly the world.

Pluripotent stem cells [cells with the capacity to develop into all cell types] offer new possibilities for off-the-shelf products. The Cell and Gene Therapy Catapult will work with these scientists to develop their products and accelerate them through clinical trials and become investable propositions, whether through spin-out companies or investment by big pharma.

In addition, we want to work with the NHS, academics, industry and the whole life sciences community to make the best potential of the wealth of experience in the Central Belt of Scotland and use it for the advantage for all of the UK.

Whats the future vision for CGT Catapult?

Our vision is a thriving industry delivering life changing advanced therapies to the world. For the UK to remain one of the most important players globally for these advanced cell and gene therapies.

We want the UK to be at the forefront of manufacture and supply of these living therapies. We want our NHS to be able to adopt them quickly and ensure they get to the right patients as quickly as possible. The UK, thanks to its favourable ecosystem including CGT Catapults activities and continued impact on it, and the continuous support by government for innovation, can stay at the forefront of that.

View post:

Bridging the cell and gene therapy gap - The Scotsman

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections at 2-Year Follow-Up of REFLECT Phase III Trial – Business…

PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared to unilateral injection.

The findings reinforce the results observed at 1.5 years post-treatment administration, which were reported in June 2021.

The REFLECT trials demonstration of a sustained, significant and safe improvement in visual acuity for LHON patients treated bilaterally with LUMEVOQ provides additional impetus for our push to gain regulatory approval, said Bernard Gilly, CEO and Co-Founder of GenSight Biologics. Patients afflicted with LHON who are losing their sight deserve access to a treatment like LUMEVOQ.

Designed under a Special Protocol Assessment with the FDA, REFLECT is a randomized, double-masked, placebo-controlled Phase III trial involving 98 subjects with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 mitochondrial gene; enrolled ND4 subjects had vision loss up to one year from onset. The ND4 mitochondrial mutation is associated with the most severe clinical form of LHON, with poor overall visual outcomes.1 All subjects received an intravitreal injection (IVT) of LUMEVOQ in their first affected eye. The second affected eye was randomized to either a second IVT of LUMEVOQ or a placebo IVT, which was administered on the same day or the following day. 48 subjects were randomized to LUMEVOQ bilateral treatment, and 50 to LUMEVOQ unilateral treatment (first-affected eye treated with LUMEVOQ, second-affected eye treated with placebo).

Significant visual acuity improvement over baseline, with better results for bilaterally injected patients

Two years after injection, the mean best-corrected visual acuity (BCVA) in LUMEVOQ-treated eyes was statistically significantly better than baseline, whereas the improvement from baseline was not statistically significant in placebo-treated eyes. The results indicate a sustained treatment effect for all subjects, with the improvement being greater among bilaterally treated patients.

Table 1: Change in Best-Corrected Visual Acuity (BCVA) versus Baseline, 2 Years after Injection

1st affected eye

2nd affected eye

Subjects bilaterallyinjected with LUMEVOQ

LUMEVOQ-0.25 LogMAR+13 ETDRS lettersp=0.0006

LUMEVOQ-0.18 LogMAR+9 ETDRS lettersp=0.01

Subjects unilaterallyinjected with LUMEVOQ

LUMEVOQ-0.16 LogMAR+8 ETDRS lettersp=0.02

PLACEBO-0.10 LogMAR+5 ETDRS lettersp=0.1 (NS)

The contralateral effect observed with placebo at 2 years is consistent with that which was documented in sham-treated eyes in the REVERSE2 and RESCUE3 trials.

Year 2 analyses also confirm the dose effect that was noted at Year 1.5: the mean BCVA at 2 years for bilaterally and unilaterally treated subjects reached 1.32 and 1.44 LogMAR, respectively, with an absolute difference between arms of +6 ETDRS letters in favor of bilaterally treated subjects.

Responder analyses point to the benefits of treatment for patients that would otherwise have experienced significant vision loss with a very low likelihood of spontaneous recovery.1 For example, 60% of the bilaterally treated patients (56% of unilaterally treated patients) who had vision above the threshold of legal blindness in at least one eye remained above the threshold at Year 2.

Efficacy demonstrated even more clearly in visual acuity improvement from nadir

Comparison against nadir (i.e., the worst BCVA recorded from baseline to Year 2) more starkly demonstrates the efficacy of LUMEVOQ, even for the placebo eyes that improved via a contralateral treatment effect.

Table 2: Change in Best-Corrected Visual Acuity (BCVA) versus Nadir, 2 Years after Injection

1st affected eye

2nd affected eye

Subjects bilaterallyinjected with LUMEVOQ

LUMEVOQ-0.39 LogMAR+20 ETDRS lettersp<0.0001

LUMEVOQ-0.34 LogMAR+17 ETDRS lettersp<0.0001

Subjects unilaterallyinjected with LUMEVOQ

LUMEVOQ-0.38 LogMAR+19 ETDRS lettersp<0.0001

PLACEBO-0.27 LogMAR+14 ETDRS lettersp<0.0001

Responder analyses indicate that the treatment effect is not limited to just a minority of subjects. Two years after injection, 73% of bilaterally treated subjects and 66% of unilaterally treated subjects had experienced a clinically meaningful improvement of at least -0.3 LogMAR (+15 ETDRS letters) relative to their observed nadir.

Table 3: Responder Analyses, Based on Change from Nadir at Year 2

Definition of Responder

-0.3 LogMAR improvement inat least one eye

Clinically Relevant Recovery*in at least one eye

Subjects bilaterallyinjected with LUMEVOQ

73%

75%

Subjects unilaterallyinjected with LUMEVOQ

66%

60%

Note: *Clinically Relevant Recovery is defined as: i) For eyes on-chart at nadir, an improvement of -0.2 LogMAR (10 ETDRS letters) from nadir; or ii) For eyes off-chart at nadir, eyes which became on-chart (i.e., BCVA 1.6 LogMAR).

Bilateral injections have a favorable safety profile

The favorable safety profile of LUMEVOQ was confirmed. There was no study discontinuation related to systemic or ocular adverse events, and there were no serious ocular adverse events. The main ocular adverse event was intraocular inflammation, which was mostly mild and responsive to conventional treatment. The favorable safety profile was comparable in unilaterally and bilaterally treated subjects.

The persistence of LUMEVOQ efficacy is remarkably consistent across the development program, so that the REFLECT results bolster the evidence provided by 3 years of data from RESTORE4 and 5 years of data from REVEAL, noted Magali Taiel, MD, Chief Medical Officer of GenSight Biologics.

Results of the 4-year follow-up of RESTORE are expected to be available in January 2022.

Dr. Taiel added, Moreover, we affirm the insight that bilateral injection of LUMEVOQ is the best option for patients with ND4 Leber Hereditary Optic Neuropathy.

REFLECT patients have been invited to participate in a long-term follow-up that will monitor the safety and efficacy of LUMEVOQ up to 5 years post-injection.

References:

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in subjects suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer subjects a sustainable functional visual recovery.

About Leber Hereditary Optic Neuropathy (LHON)

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 1,200-1,500 new subjects who lose their sight every year in the United States and the European Union.

About LUMEVOQ (GS010; lenadogene nolparvovec)

LUMEVOQ (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. LUMEVOQ was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018.

About REFLECT

REFLECT is a multi-center, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of bilateral injections of GS010 in subjects with LHON due to the NADH dehydrogenase 4 (ND4) mutation. In the active arm, GS010 was administered as a single intravitreal injection in each eye of each subject. In the placebo arm, GS010 was administered as a single intravitreal injection to the first affected eye, while the fellow eye received a placebo injection.

The primary endpoint for the REFLECT trial is the BCVA reported in LogMAR at 1.5 years (78 weeks) post-treatment in the second-affected/not-yet-affected eye. The change from baseline in second-affected/not-yet-affected eyes receiving GS010 and placebo is the primary response of interest. The secondary efficacy endpoints include: BCVA reported in LogMAR at 2 years post-treatment in the second-affected/not-yet-affected eye compared to both placebo and the first-affected eye receiving GS010, OCT and contrast sensitivity and quality of life scales.

The trial was conducted in multiple centers across Europe (1 each in France, Spain, Italy and the UK), the US (6 centers) and Taiwan (1 center). The trial planned to enroll 90 subjects with vision loss up to 1 year in duration; 98 subjects were successfully screened and treated. The first subject was treated in March 2018 and the last one in July 2019.

ClinicalTrials.gov Identifiers:REFLECT: NCT03293524

See the original post here:

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections at 2-Year Follow-Up of REFLECT Phase III Trial - Business...

Sports gambling passes Ohio legislature after years of debate and now heads to the governor – WOUB

By: Karen Kasler | Statehouse News BureauPosted on: Thursday, December 9, 2021

COLUMBUS, Ohio (Statehouse News Bureau) A bill thats on its way to Gov. Mike DeWine would legalize sports gambling in Ohio starting before January 1, 2023. State lawmakers have been working on the issue since the US Supreme Court allowed states to set up sports betting in 2018.

The bill, which adds gambling language to aHouse bill on veterans ID cards, puts oversight over sports betting with the Ohio Casino Control Commission. Sen. Kirk Schuring (R-Canton) has been at the front of the negotiations.

We all know that sports gaming is going on right now as we speak, illegally, Schuring said on the Senate floor. As were going to put the necessary regulatory guardrails around it to make sure it is done correctly here in Ohio.

The bill would set up 25 Class A licenses for mobile betting with the first sports book contract costing $3 million and the second going for $10 million. 40 Class B licenses will be allowed for brick and mortar betting at casinos and racinos and for professional sports teams, and thousands of Class C licenses for liquor permit holders to have betting kiosks. It would also impose a 10% tax on gaming receipts, with the money going to education. If its signed, sports betting could start before January 1, 2023.

For years lawmakers have discussed sports gambling and which entity would have oversight. Before adding their language to this bill, the Senatepassed a bill earlier this yearputting sports gambling under the Casino Control Commission. The House passed a bill last year to putthe authority over sports betting with the Ohio Lottery.

Continued here:

Sports gambling passes Ohio legislature after years of debate and now heads to the governor - WOUB

Could NFTs Disrupt the Gambling Business? – Motley Fool

There's an NFT on the Ethereum (CRYPTO:ETH) blockchain that is hoping to upend the online gambling market. On Tuesday the Slotie NFT from Elia Software hit the market, and it could be the first NFT to generate real money from gambling.

As NFTs become more popular and cryptocurrencies and the blockchain grow, NFT projects are becoming more and more innovative. We aren't just talking about a cool piece of art here -- this project is intended to be a long-term investment.

Image source: Getty Images.

Slotie is the name for a set of 10,000 unique NFTs minted on Tuesday. Sloties cost 0.08 Ethereum for the first 2,500 pre-sale mints, and 0.16 Ethereum for 7,000 public sale mints, or about $5.7 million.

These NFTs are said to provide real-world benefits at 150 casinos around the world and "Exclusive Holders Rewards".The first reward is a Slotie-themed game for crypto casinos, which will pay out a 12% commission to each partner. 80% of that payment goes to Slotie holders. Slotie NFT holders will also get a 20% rakeback at participating casinos, which means they'll get 20% of the casino's take back as a benefit.

The key to the economics of this system is a token that can be transferred to NFT owners on the blockchain.

Slotie is using a token called WATT, which is kind of like a gem you earn in a game depending on how you play and what you own. In this case, WATTs are earned on a daily basis depending on the qualities of a Slotie. Here's how the token is described by Slotie:

WATTs is a token which acts like the energy in the Sloties' world. WATTs are generated on a daily basis. Every Slotie owner gets 10 WATTs tokens daily. You will have enough WATTs to breed your Sloties in 3 months. For those who can't wait to get their Junior Sloties, there's the opportunity to buy tokens from other owners on the secondary market.

What Slotie's developers would like to do is make WATTs valuable by creating uses for them. Breeding, slot events, and potentially other benefits will be available. But the real hope is that WATTs have a monetary value.

WATTs will be paid to Slotie holders, but they will need to then be exchanged into Ethereum or another coin. This will allow Slotie owners to cash out benefits, but a market needs to be created for the token -- and it appears right now that WATT tokens won't be generated by Slotie NFT holders until the first or second quarter of 2022.

One secret of NFTs is that the development team is often paid with an allocation of tokens. Slotie didn't disclose how many WATTs the team will get, but this is often a sizable amount.

The main use for WATTs is what's known as breeding. Breeding takes 1,800 WATTs and 2 Sloties and creates a Junior Slotie. However, there doesn't seem to be any real utility for the Junior Slotie until at least the third quarter of 2022.

Future games and partnerships could be beneficial to Slotie holders, but that's a ways down the roadmap.

This is one of the first real-world projects I've seen with the backing of a legitimate company with locations around the world. But the Slotie NFT still relies on these developers staying engaged and building value long-term. If casinos don't sign up or WATT doesn't hold value, there will be no value for this NFT outside of the art.

Slotie also ran into huge problems during its mint, with scammers overwhelming the developers and many people missing the mint altogether. It's still unclear on secondary markets which Sloties are the real ones and which are scams, a huge problem with NFTs in their infancy.

As utility NFTs like Slotie hit the market, it will be interesting to watch how they play out. This could be a great way to generate indirect, passive income from an industry like online gambling. But it could end in disaster if buyers lose confidence in the project. And this is an NFT from a company, so it may be difficult to build a passionate following organically.

Time will tell where this NFT goes, but if you're looking for innovation in NFTs, this is one to watch.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Read more here:

Could NFTs Disrupt the Gambling Business? - Motley Fool

The 9 Best Movies About Gambling – Film Threat

Gambling is a topic that always sparks interest. It can be exciting, thrilling, and addicting all at the same time. For some people, gambling is their life-blood, and for others, its just an occasional hobby. When do you think about gambling? What comes to mind?

There are many great movies about gambling out there, but we have narrowed them down to the top nine favorites:

This is the first James Bond movie that Daniel Craig plays in. Its set during his early years as a spy and doesnt include gadgets, sexy women, or high-stakes action. However, it shows how he was recruited into MI-26 and what he had to do to prove himself worthy of being 00 status. If you love poker, this would be great for you because you can find your casino bonus in multiple scenes where they play Texas Holdem Poker!

Based on true events, this movie shows what happened when MIT students got together and created their card counting system to beat casinos out of millions of dollars. Kevin Spacey stars in this drama that also has some comedic elements mixed in there too. Its one for all audiences but especially those with an interest in math or gambling.

This movie is more about the emotional side of gambling and what happens when things go wrong. Its also a great drama with Bill Campbell playing an older man who works as a cooler at casinos because he brings everyone bad luck. When they lose everything, Bernie Mac shows up to help him out, but even though it doesnt look like their relationship will work, there are some surprising twists in this one.

Daniel Day-Lewis gives another wonderful performance in this Oscar-winning film by Paul Thomas Anderson, where his character becomes obsessed with oil, power, and greed. Hell do anything to get ahead, including using someone elses money without telling them, which leads to dire consequences for all involved, especially since most people dont know how much hes worth.

This is the first time Mel Gibson and Jodie Foster appeared together on screen. They play a father/daughter duo who runs a traveling poker game throughout Texas. Still, things heat up when they meet James Garners character Bret Maverick, their biggest competition. If you love Westerns, especially ones with lots of comedy mixed in, then definitely check this one out and all the other great movies above.

Eric Bana stars as Huck Cheever, a young professional gambler from Los Angeles that makes his living off playing short-term poker games. He gets into hot water after he bets against his hand at an important high-stakes match forcing him to go on vacation with his estranged father, L.C. Cheever (Robert Duvall), who hasnt spoken to him in years. This movie shows their journey together as they try and rebuild their bond while Huck tries his best not to lose everything at the poker table this time around too.

Miles and Worm go headtohead against Teddy KGB in an all-out war over 15,000 dollars, leading them down a dangerous path towards revenge and betrayal. Not only with each other but also from the Russian mobster.

This movie is a remake of the 1974 film starring James Caan. It takes place in Las Vegas and follows Jim Bennett, an English professor with a severe gambling addiction who owes money to dangerous people. Hes forced to look for more high-risk opportunities if he wants his problems fixedfast! When things go south on him again, though, will it be too much for him to handle?

This movie takes place in New Orleans and follows Jack, an aspiring novelist looking to pay off his debts by working as a dealer at one of the best casinos around. He quickly becomes obsessed with gambling, but things take a turn for him when he gets involved in illegal games behind-the-scenes that end up getting him into some hot water.

These are nine of the best movies about gambling out there. Whether youre interested in learning more, need a little inspiration to get your game on again, or just want something great to watch this weekend, we hope that you find one (or all) of these films entertaining and enjoyable.

See more here:

The 9 Best Movies About Gambling - Film Threat

Gambling-law violations alleged during first three months of Deadwood sports betting – SDPB Radio

State regulators are alleging five violations of gambling laws during the first three months of sports betting in Deadwood.

The allegations involve a total of 12 casinos, betting operators and workers.

The new gambling option began Sept. 9 and is limited to the city of Deadwood. The accusations are made by the Commission on Gaming, which meets Wednesday.

Most of the allegations relate to accepting sports bets of more than $1,000 the state limit. The commission can punish the violations by revoking or suspending gaming licenses. It can also impose fines up to $100,000 per violation.

Some of the casinos, operators and workers have come to agreements with the commission that say they admit or don't deny the conduct alleged in the complaint.

Allegations

Internet Sports International is accused of accepting a $1,550 bet Sept. 18 at the Gold Dust casino on the Tampa Bay Buccaneers vs. Atlanta Falcons game.

Cadillac Jack's and its operator BetMGM are accused of accepting a $3,000 bet for the same game on the same day.

Cadillac Jack's and BetMGM are also accused of accepting a $1,300 bet Sept. 20 on the Detroit Lions vs. Green Bay Packers game.

BetMGM has a third accusation for accepting a $1,500 bet Sept. 19 at Tin Lizzie on the Philadelphia Eagles vs. Miami Dolphins game.

Deadwood Mountain Grand and operator IGT are accused of a different kind of violation. They allegedly allowed seven futures bets for the World Series on Oct. 26, even though futures aren't allowed under state law.

Resolved cases

Tin Lizzie was accused of failing to notify the commission when it learned on Sept. 19 that its sports betting system was capable of accepting bets over $1,000. The casino has agreed to pay a $1,000 fine. It will be fined $1,500 more if it has another violation in the next 12 months.

A casino worker has agreed to a $350 fine after being accused of failing to notify the commission after issuing a $1,500 wager on Sept. 19. The wager was on the Eagles v. Dolphins game.

Two workers have admitted to issuing the $3,000 bet Oct. 18 on the Buccaneers v. Falcons game. One will be fined $350 and the other will be fined $150.

Another worker will pay a $150 fine after admitting to issuing the $1,300 wager Sept. 20 on the Lions v. Packers game.

Two workers will be fined $150 each after admitting to accepting the futures bets on Oct. 26.

View original post here:

Gambling-law violations alleged during first three months of Deadwood sports betting - SDPB Radio

BGC Unveils Ad Tech Forum to Protect the Youth from Gambling Ads – GamblingNews.com

Britains Betting and Gaming Council has unveiled a new cross-industry Ad Tech Forum. The forums work will be to provide operators with crucial tips on how to better protect the youth from gambling harm.

The Ad Tech Forums work will heavily trust data collection technologies. It will have operators, such as Bet365, Flutter, and William Hill, collaborate with Google, Meta, Snap, and Twitter to better understand problem gambling and work to inhibit it through strategic usage of data. By using cutting-edge solutions, the forum and the bookmakers will aim to improve gambling ads targeting and avoid exposing minors to betting commercials.

The new Ad Tech Forum has received the support of the Advertising Association. The latters chief executive officer, Stephen Woodford, spoke on the matter. He said that he and the association welcome the gambling industrys proactive work alongside big tech platforms and advertising bodies.

It is essential that gambling ads online and in social media meet the highest standards of social responsibility, Woodford reminded.

The forum will fully comply with the mandatory measures and commitments from the Sixth Industry Code for Socially Responsible Advertising, described by the Betting and Gaming Council. This means that all operators who are a part of the BGC must make sure that their adverts target only people who are aged 25 or older. Furthermore, the ads have to adopt safer messages, instead of tripping people into gambling away large sums of money.

Michael Dugher, the chief executive officer of the Betting and Gaming Council, known as an ardent fighter for a healthier gambling industry, also spoke on the Ad Tech Forum. He revealed that he is delighted that the BGC has been able to coordinate the Ad Tech Forum. Dugher is convinced that the forums tech and data-based approach will help to crush gambling harm among the youth and vulnerable groups.

Dugher emphasized that ever since the BGCs establishment two years ago, it has tirelessly worked to drive up standards and promote safer gambling. For him, the Ad Tech Forum attests to the councils continued commitment to a safer gambling ecosystem.

Several days ago, Dugher once again spoke about how crucial it is to avoid exposing young people to gambling content. He appealed to the British government, asking it to place child protection at the front and center of the next gambling white paper. Several weeks ago, the council praised Facebook for allowing users to turn off gambling-related ads.

Read more here:

BGC Unveils Ad Tech Forum to Protect the Youth from Gambling Ads - GamblingNews.com

Tax Tips on Gambling Winnings and Losses | Professionals’ Columns | thechiefleader.com – The Chief-Leader

Whether you roll the dice, bet on the ponies, play cards or enjoy the slot machines, you should know that as a casual gambler, your winnings are fully taxable and must be reported on your income-tax return. You can also deduct your gambling losses, but only up to the extent of your winnings.

Here are five important tips about gambling and taxes:

For example, this occurs if you win:

On the Form W-2G, Federal taxes are withheld at a flat rate of 24 percent.

Before you celebrate the "big win," put some money aside for Uncle Sam, because if you win, he wins! Refer to IRS Publication 529, "Miscellaneous Deductions," for more details and information.

Barry Lisak is an IRS Enrolled Agent, meaning that he has passed special U.S. Treasury Department exams that qualify him to represent clients dealing with audits or tax-resolution cases. Any questions can be directed to him at (516) TAX-SAVE, or mrbarrytax@aol.com.

We depend on the support of readers like you to help keep our publication strong and independent.Join us.

Follow this link:

Tax Tips on Gambling Winnings and Losses | Professionals' Columns | thechiefleader.com - The Chief-Leader

Chipz The Biggest DeFi Project To Hit The Gambling Industry – Block Telegraph

This year weve seen the world of DeFi impact industries around the world. Its impacted the way we complete transactions, the way we game, and even the way we collect art. Now an innovative new project is using the same blockchain technology to change the way we bet. Chipz is an exciting crypto-based gambling platform that allows users to make a bet on literally anything they want. If theres a betting market for the topic, it can be found on the platform. With a range of exciting new features and a roadmap planned out for Q2 of 2022, its no surprise that Chipz has got the world of DeFi excited.

Chipz is a new crypto-based gambling platform looking to take crypto betting to a whole new level. The platform allows users to make bets on any topic they can imagine, from sports such as MMA, the NBA, and the NFL, to politics, gaming, and even the future price of the cryptocurrency. The project itself was created in Costa Rica and plans to go live this December after much anticipation from its audience.

The developers have used blockchain technology to take the world of betting a step further than before. In the past, players would have to move between platforms based on what they wanted to bet on. With Chipz, they can find everything in one place, using USDC to place their bets.

As well as using blockchain technology to innovate what players bet on, its also been used to create several exciting new features for players to enjoy. Here are some that already have the industry talking.

For every transaction made, 3% will be taken and placed into a revenue share pool. Investors within this shared pool can stake their own tokens, allowing them to earn from the tokens theyve staked.

Throughout the year, Chipz will hold a range of DeFi betting events based on major world events happening during that time period. This could include political elections, the outcome of market fluctuations, and championship sports matches to name a few.

In the past, bookmaking could be an expensive option for players. They would often have to pay around $5 a week before theyd even made a bet. Chipz is looking to change that, providing a more affordable option for players. They offer deals as low as $60 for a year, without limits. They also plan to provide giveaways to early buyers who want to get in before the end of the year.

Chipz is an ERC 20 utility token thats used to power the Chipz network. Its currently traded on Binance Smart Chain (BSC) Uniswap and Pancake Swap, with the team planning to make it more widely available by the end of 2021.

An exciting feature of CHIPZ is that players can speculate on its value whilst playing a game. This means that players can profit during their bets when the CHIPZ token is increasing in value. To make things more exciting, the platform also has an option of a 15% APY staking reward whilst a bet is in play. For example, two friends can bet on the result of the Champions League final. Once the bet is placed, players can earn a yield of up to 15% during the game, taking excitement to a whole new level.

One of the most exciting aspects of Chipz is the team behind the project. Not only is the team itself full of experienced industry veterans, but these experts have a team of knowledgeable advisors supporting them. Team members include Joab Garza, who developed the hit NFT game, Tezatopia and Justin Lally, who is a member of the Bitcoin Foundation. Together, the two have formed a team of blockchain experts who are ready to take the gambling world by storm. Theyre backed by an advisory board consisting of several famous names, including Jacob Busch from the Anheuser Busch family, the owner of Golden Knights, Gavin Maloof, and NFL Star Todd Duckett.

With many promising features and a motivated team behind the project, its fair to say that Chipz is a project we will see in the spotlight in the future. Launching later this month, its community is extremely excited to see what Chipz brings to the world of gambling and how its new technology revolutionizes the way players choose to place their bets.

More here:

Chipz The Biggest DeFi Project To Hit The Gambling Industry - Block Telegraph

Voice of the People: Shining a light on the youth gambling problem – Kankakee Daily Journal

Focus Youth Gambling Prevention is a prevention program of the Illinois Association for Behavioral Health. I want to raise awareness of an issue rapidly growing in Illinois youth gambling. On average, youth are exposed to gambling at age 10, which is earlier than alcohol, tobacco, and other drugs. The earlier youth are exposed, the more likely they are to have a gambling problem later in life. Adolescent prevalence rates of problem gambling are 2-4 times that of adults. Youth who gamble are more likely to have mental health challenges, more likely to partake in drinking, smoking, and drugs, and more likely to be involved in criminal behaviors.

Here at Focus, we are trying to prevent youth from participating in gambling activities. Focus Youth Gambling Prevention is a statewide youth prevention program that provides students with many programming opportunities to build skills in advocacy, leadership, public speaking, and youth gambling prevention education. Our mission is to prevent underage gambling and create positive change in communities through student advocacy, youth leadership development, and gambling prevention campaigns.

But why would schools and communities want to implement Focus? This program is for youth leaders who want a seat at the table, to share their own perspectives, and to use their voices. Youth groups can be at the forefront of this rising issue and participate in prevention efforts to create healthier and safer communities statewide.

We are reaching out in the hopes of this being highlighted because of the need to raise awareness and to involve youth groups to participate in Focus in their communities. Focus Youth Gambling Prevention is a program of the Illinois Association for Behavioral Health and is funded in whole by the Illinois Department of Human Services, Division of Substance Use Prevention and Recovery through a grant from the Substance Abuse and Mental Health Services Administration.

Focus Youth Gambling Prevention

See the rest here:

Voice of the People: Shining a light on the youth gambling problem - Kankakee Daily Journal

‘It’s really tearing neighborhoods apart’: Bibb looks to restrict gambling machines in businesses – 13WMAZ.com

Commissioner Virgil Watkins is proposing tighter restrictions on stores with coin-operated gambling machines.

MACON, Ga. Bibb County Commissioner Virgil Watkins is proposing tighter restrictions on stores with coin-operated gambling machines.

Watkins' proposed ordinance says businesses can't have these machines within 1,500 feet of any liquor store, or 2,500 feet of small convenience stores that don't have fuel or fresh food.

Kay Reynolds has lived in east Macon for close to 20 years now.

"People are throwing away their money that they need to work and pay bills, care for their families and their children, but they're spending it on them stupid machines," said Reynolds.

For Reynolds, safety is paramount, "People take children into these stores and that's not an environment for children, and they're open 24 hours. It's not good, it's not safe, I don't trust them."

Donshay Caldwell says he's ready for a change.

"I see people every day on the machines gambling, every single day. Everybody has a goal to live a comfortable life, so when people have that type of desire, I feel like the machines are there to create a false sense of euphoria," said Caldwell.

Caldwell says people need other opportunities like better jobs.

"It preys on mental health also because you become pretty much addicted to them. When people excessively spend money, money, money that they don't necessarily have to make ends meet, I feel like that causes a problem," said Caldwell.

Both agree they want what's best for the community.

"It's really tearing neighborhoods apart. It's getting in more bad people that don't need to be in the neighborhoods. I don't feel comfortable going into the stores with all of the people in there gambling. If they want to gamble, go to the casinos -- that's what they're for, to gamble," said Reynolds.

"It's a product and people are consuming it. I just feel like it's bad for the community," said Caldwell.

According to the proposal, if a business is found operating gambling machines within the restricted areas, they could get fined at least $500 per day.

Watkins' proposal also says, under his plan, coin-operated machines could not be located near churches, public libraries, rec centers, alcohol treatment centers, public housing, or schools or colleges.

Originally posted here:

'It's really tearing neighborhoods apart': Bibb looks to restrict gambling machines in businesses - 13WMAZ.com